Captopril

Captopril is filed as Angiotensin Converting Enzyme Inhibitor [EPC]. The sections below restate public label fields stored for this profile.

Class
Angiotensin Converting Enzyme Inhibitor [EPC]
Route
ORAL
Dosage forms
HOW SUPPLIED Captopril Tablets, USP are available containing 12.5 mg, 25 mg, 50 mg or 100 mg of captopril, USP. The 12.5 mg tablets are white to off-white, arc diamond shaped tablets with bisect on one side and “131” on the other side. They are available as follows: Bottles of 100 Tablets NDC 69292-522-01 Bottles of 1000 Tablets NDC 69292-522-10 The 25 mg tablets are white to off-white, arc diamond shaped tablets with quadrisect on one side and “132” on the other side. They are available as follows: Bottles of 100 Tablets NDC 69292-524-01 Bottles of 1000 Tablets NDC 69292-524-10 The 50 mg tablets are white to off-white, arc diamond shaped tablets with bisect on one side and “133” on the other side. They are available as follows: Bottles of 100 Tablets NDC 69292-526-01 Bottles of 1000 Tablets NDC 69292-526-10 The 100 mg tablets are white to off-white, capsule shaped tablets with bisect on one side and “134” on the other side. They are available as follows: Bottles of 100 Tablets NDC 69292-528-01 Bottles of 500 Tablets NDC 69292-528-50 Bottles contain a desiccant-charcoal canister. All captopril tablets are white and may exhibit a slight sulfurous odor.
Generic available
Yes
Manufacturer
AMICI PHARMACEUTICALS LLC
Boxed warning
Yes

Approved uses

Hypertension: Captopril tablets, USP are indicated for the treatment of hypertension. In using captopril tablets, consideration should be given to the risk of neutropenia/agranulocytosis (see WARNINGS ). Captopril tablets may be used as initial therapy for patients with normal renal function, in whom the risk is relatively low. In patients with impaired renal function, particularly those with collagen vascular disease, captopril should be reserved for hypertensives who have either developed unacceptable side effects on other drugs, or have failed to respond satisfactorily to drug combinations. Captopril tablets are effective alone and in combination with other antihypertensive agents, especially thiazide-type diuretics. The blood pressure lowering effects of captopril and thiazides are approximately additive.

How it works

The mechanism of action of captopril has not yet been fully elucidated. Its beneficial effects in hypertension and heart failure appear to result primarily from suppression of the renin-angiotensin-aldosterone system. However, there is no consistent correlation between renin levels and response to the drug. Renin, an enzyme synthesized by the kidneys, is released into the circulation where it acts on a plasma globulin substrate to produce angiotensin I, a relatively inactive decapeptide. Angiotensin I is then converted by angiotensin converting enzyme (ACE) to angiotensin II, a potent endogenous vasoconstrictor substance. Angiotensin II also stimulates aldosterone secretion from the adrenal cortex, thereby contributing to sodium and fluid retention. Captopril prevents the conversion of angiotensin I to angiotensin II by inhibition of ACE, a peptidyldipeptide carboxy hydrolase. This inhibition has been demonstrated in both healthy human subjects and in animals by showing that the elevation of blood pressure caused by exogenously administered angiotensin I was attenuated or abolished by captopril. In animal studies, captopril did not alter the pressor responses to a number of other agents, including angiotensin II and norepinephrine, indicating specificity of action. ACE is identical to "bradykininase", and captopril may also interfere with the degradation of the vasodepressor peptide, bradykinin. Increased concentrations of bradykinin or prostaglandin E 2 may also have a role in the therapeutic effect of captopril. Inhibition of ACE results in decreased plasma angiotensin II and increased plasma renin activity (PRA), the latter resulting from loss of negative feedback on renin release caused by reduction in angiotensin II. The reduction of angiotensin II leads to decreased aldosterone secretion, and, as a result, small increases in serum potassium may occur along with sodium and fluid loss. The antihypertensive effects persist for a longer period of time than does demonstrable inhibition of circulating ACE. It is not known whether the ACE present in vascular endothelium is inhibited longer than the ACE in circulating blood.

Boxed warning

WARNING: FETAL TOXICITY When pregnancy is detected, discontinue captopril tablets as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. See WARNINGS: Fetal Toxicity

Warnings and precautions

Presumably because angiotensin-converting enzyme inhibitors affect the metabolism of eicosanoids and polypeptides, including endogenous bradykinin, patients receiving ACE inhibitors (including captopril) may be subject to a variety of adverse reactions, some of them serious.

Contraindications

Captopril tablets are contraindicated in patients who are hypersensitive to this product or any other angiotensin-converting enzyme inhibitor (e.g., a patient who has experienced angioedema during therapy with any other ACE inhibitor). Do not co-administer aliskiren with captopril in patients with diabetes (see PRECAUTIONS: Drug Interactions ). Captopril tablets are contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). Do not administer captopril within 36 hours of switching to or from sacubitril/valsartan, a neprilysin inhibitor (see PRECAUTIONS, Drug Interactions ).

Adverse reactions

Reported incidences are based on clinical trials involving approximately 7,000 patients.

Dosage and administration

Captopril tablets should be taken one hour before meals. Dosage must be individualized.

Drug interactions

Drug Interactions Dual Blockade of the Renin-Angiotensin System (RAS) Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy. Most patients receiving the combination of two RAS inhibitors do not obtain any additional benefit compared to monotherapy. In general, avoid combined use of RAS inhibitors. Closely monitor blood pressure, renal function and electrolytes in patients on captopril tablets and other agents that block the RAS. Do not coadminister aliskiren with captopril tablets in patients with diabetes. Avoid use of aliskiren with captopril tablets in patients with renal impairment (GFR < 60 ml/min). Non-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors) In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, coadministration of NSAIDs, including selective COX-2 inhibitors, with ACE inhibitors, including captopril, may result in deterioration of renal function, including possible acute renal failure. These effects are usually reversible. Monitor renal function periodically in patients receiving captopril and NSAID therapy. The antihypertensive effect of ACE inhibitors, including captopril, may be attenuated by NSAIDs. Hypotension–Patients on Diuretic Therapy Patients on diuretics and especially those in whom diuretic therapy was recently instituted, as well as those on severe dietary salt restriction or dialysis, may occasionally experience a precipitous reduction of blood pressure usually within the first hour after receiving the initial dose of captopril. The possibility of hypotensive effects with captopril can be minimized by either discontinuing the diuretic or increasing the salt intake approximately one week prior to initiation of treatment with captopril tablets or initiating therapy with small doses (6.25 or 12.5 mg). Alternatively, provide medical supervision for at least one hour after the initial dose. If hypotension occurs, the patient should be placed in a supine position and, if necessary, receive an intravenous infusion of normal saline. This transient hypotensive response is not a contraindication to further doses which can be given without difficulty once the blood pressure has increased after volume expansion. Agents Having Vasodilator Activity Data on the effect of concomitant use of other vasodilators in patients receiving captopril tablets for heart failure are not available; therefore, nitroglycerin or other nitrates (as used for management of angina) or other drugs having vasodilator activity should, if possible, be discontinued before starting captopril tablets. If resumed during captopril tablets therapy, such agents should be administered cautiously, and perhaps at lower dosage. Agents Causing Renin Release Captopril’s effect will be augmented by antihypertensive agents that cause renin release. For example, diuretics (e.g., thiazides) may activate the renin-angiotensin-aldosterone system. Agents Affecting Sympathetic Activity The sympathetic nervous system may be especially important in supporting blood pressure in patients receiving captopril alone or with diuretics. Therefore, agents affecting sympathetic activity (e.g., ganglionic blocking agents or adrenergic neuron blocking agents) should be used with caution. Beta-adrenergic blocking drugs add some further antihypertensive effect to captopril, but the overall response is less than additive. Agents Increasing Serum Potassium Since captopril decreases aldosterone production, elevation of serum potassium may occur. Potassium-sparing diuretics such as spironolactone, triamterene, or amiloride, or potassium supplements should be given only for documented hypokalemia, and then with caution, since they may lead to a significant increase of serum potassium. Salt substitutes containing potassium should also be used with caution. Lithium Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and ACE inhibitor therapy. These drugs should be coadministered with caution and frequent monitoring of serum lithium levels is recommended. If a diuretic is also used, it may increase the risk of lithium toxicity. Cardiac Glycosides In a study of young healthy male subjects no evidence of a direct pharmacokinetic captopril-digoxin interaction could be found. Loop Diuretics Furosemide administered concurrently with captopril does not alter the pharmacokinetics of captopril in renally impaired hypertensive patients. Allopurinol In a study of healthy male volunteers no significant pharmacokinetic interaction occurred when captopril and allopurinol were administered concomitantly for 6 days.

Common questions

What is Captopril approved to treat?

According to its FDA label, Captopril is approved for: Hypertension: Captopril tablets, USP are indicated for the treatment of hypertension. In using captopril tablets, consideration should be given to the risk of neutropenia/agranulocytosis (see WARNINGS ). Captopril tablets may be used as initial therapy for patients with normal re… For medical advice, please talk to your prescriber or pharmacist.

What class of drug is Captopril?

Captopril belongs to the Angiotensin Converting Enzyme Inhibitor [EPC] class of medications.

What form does Captopril come in?

The FDA label lists Captopril as: HOW SUPPLIED Captopril Tablets, USP are available containing 12.5 mg, 25 mg, 50 mg or 100 mg of captopril, USP. The 12.5 mg tablets are white to off-white, arc diamond shaped tablets with bisect on one side and “131” on the other side. They are available as follows: Bottles of 100 Tablets NDC 69292-522-01 Bottles of 1000 Tablets NDC 69292-522-10 The 25 mg tablets are white to off-white, arc diamond shaped tablets with quadrisect on one side and “132” on the other side. They are available as follows: Bottles of 100 Tablets NDC 69292-524-01 Bottles of 1000 Tablets NDC 69292-524-10 The 50 mg tablets are white to off-white, arc diamond shaped tablets with bisect on one side and “133” on the other side. They are available as follows: Bottles of 100 Tablets NDC 69292-526-01 Bottles of 1000 Tablets NDC 69292-526-10 The 100 mg tablets are white to off-white, capsule shaped tablets with bisect on one side and “134” on the other side. They are available as follows: Bottles of 100 Tablets NDC 69292-528-01 Bottles of 500 Tablets NDC 69292-528-50 Bottles contain a desiccant-charcoal canister. All captopril tablets are white and may exhibit a slight sulfurous odor.; oral route. Available strengths and packaging vary by manufacturer.

Is there a generic version of Captopril?

Yes. A generic version of Captopril is available in the U.S. Ask your pharmacist about substitution.

Does Captopril have a Boxed Warning?

Yes. The FDA label for Captopril carries a Boxed Warning. Excerpt: "WARNING: FETAL TOXICITY When pregnancy is detected, discontinue captopril tablets as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. See WARNI…" See the full FDA label for the complete warning. For medical advice, please talk to your prescriber or pharmacist.

Is Captopril currently under recall?

The FDA Enforcement Report does not show an active/ongoing recall for Captopril in our latest ingest. Recall data can change daily — verify at FDA.gov.

When was Captopril approved by the FDA?

The FDA record lists the approval date for Captopril as 1997-05-30.

Who makes Captopril?

The FDA label lists AMICI PHARMACEUTICALS LLC as a labeler/manufacturer of Captopril. Multiple firms may market generics of the same molecule.

How should Captopril be stored?

The FDA label states: "Captopril Tablets, USP are available containing 12.5 mg, 25 mg, 50 mg or 100 mg of captopril, USP. The 12.5 mg tablets are white to off-white, oval, flat, beveled-edge tablets, debossed with “S1” on one side and partial…" Follow the packaging insert for the authoritative guidance.

On this site

Related medications in this class or category

Loading full data from Know Your Drugs Institute…